Driven by innovation and guided by nature

We are an early clinical development stage pharmaceutical company committed to the rapid generation of investigational new drugs for diseases with high unmet medical need. Axcentua is pioneering "crystal re-engineering" of natural compounds as an alternative drug development strategy to arrive at novel drugs with clear clinical benefits much faster, with less risk and at a fraction of the cost spent when using traditional drug development strategies. Using Axcentua’s crystal re-engineering strategy, the company has developed their lead compound AXP107-11, a multi-targeted small-molecule that kills cancer cells by multiple mechanisms and makes tumors more sensitive to the effects of chemotherapy and also prevent or reduce the risk for disease recurrence. The compound is intended to be used for treatment of a number of solid tumors such as pancreatic cancer and non-small cell lung cancer (NSCLC) and targeted to enter clinical studies in beginning of 2010.